-+ 0.00%
-+ 0.00%
-+ 0.00%

Arbutus says FDA grants Fast Track designation for imdusiran in chronic hepatitis B

PUBT·04/15/2026 11:31:18
Listen to the news
Arbutus says FDA grants Fast Track designation for imdusiran in chronic hepatitis B
  • FDA granted Fast Track designation to Arbutus for imdusiran to treat chronic hepatitis B.
  • Designation could speed development and FDA review for the program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arbutus Biopharma Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604150730PRIMZONEFULLFEED9689778) on April 15, 2026, and is solely responsible for the information contained therein.